Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine diseases, announced the appointment of Neil Aubuchon as Chief Commercial Officer. Aubuchon brings more than 20 years of experience in the biopharmaceutical industry, with leadership roles across global commercial and marketing organizations and a strong background in cardiometabolic therapies.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
Brian Lian, Ph.D., Chief Executive Officer of Viking Therapeutics, said the company is strengthening its commercial capabilities as it advances its pipeline of metabolic therapies. He noted that Viking’s lead program, VK2735, a dual GLP 1 and GIP receptor agonist currently in Phase 3 trials for obesity, represents a significant opportunity. Lian explained that Aubuchon’s experience makes him well suited to lead the commercialization strategy for VK2735, including engagement with potential strategic partners, as the company prepares for future commercial execution.
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
Before joining Viking, Aubuchon served as Chief Commercial Officer at AbCellera, where he led the development of the company’s overall commercial strategy. Prior to that role, he was Global Marketing Lead for Amgen’s general medicine early portfolio, overseeing integrated commercial planning across non oncology therapeutic areas and guiding strategy for more than ten development programs, including those in cardiometabolic disease. Earlier in his career, Aubuchon spent nearly 17 years at Eli Lilly, holding a range of senior commercial positions. His roles included Chief Marketing Officer in Australia and Japan, Head of Strategy and Operations for Lilly Bio Medicines globally, and Vice President of Lilly Bio Medicines in Japan.
Aubuchon said the field of metabolic medicine is undergoing rapid change, with new therapies offering meaningful benefits for people living with obesity and related conditions. He added that VK2735 stands out for its potential best-in-class profile and said he looks forward to working with the Viking team to engage healthcare stakeholders and help bring the company’s metabolic portfolio to patients in a complex and evolving healthcare environment.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
